Tumors in urological patients C64 C61 C67 C65 C66 C60 C62 C63
Conditions
Interventions
Group 1: Patients with urological tumors
Patients suspected of having a urological carcinoma (prostate, renal cell, testicular, ureteral, renal pelvis, or bladder cancer) undergo surgical treatment.
Sponsors
Universitätsklinikum Ulm
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients (=18 years of age) who are capable of being informed and who have a urological tumor or the suspicion of the presence of a tumor disease, available written declaration of consent
Exclusion criteria
Exclusion criteria: Lack of consent from the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overarching goal is to establish a biobank of tissue (confirmatory tumor and metastases, control tissue), blood, urine, stool as well as organoids, immune cells and stroma cells stromal cells (in the sense of a living biobank) from patients with urological tumors and tumors as well as control patients who have an underlying urological disease and are therefore undergoing disease and are therefore undergoing surgery, but do not have a tumor disease. have tumor disease. On the other hand, tissue from tumor patients that has nothing to do with the with the tumor disease are used as a control (e.g. renal pelvis tissue in renal cell carcinoma). renal pelvis tissue in renal cell carcinoma, see below). | — |
Secondary
| Measure | Time frame |
|---|---|
| In addition, further therapy-relevant data (see below) will be collected prospectively. For this purpose different data parameters are obtained in addition to the biomaterials. The biobank serves as the basis for various other translational approaches to improve the improve the diagnosis and treatment of urological tumor entities in the future. | — |
Countries
Germany
Contacts
Public ContactFelix Wezel
Universitätsklinikum Ulm
Outcome results
None listed